These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3327449)

  • 1. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine.
    Wang M; Tew KD; Stearns ME
    Anticancer Res; 1987; 7(6):1165-71. PubMed ID: 3327449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells.
    Sheridan VR; Speicher LA; Tew KD
    Eur J Cell Biol; 1991 Apr; 54(2):268-76. PubMed ID: 1879438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.
    Mareel MM; Storme GA; Dragonetti CH; De Bruyne GK; Hartley-Asp B; Segers JL; Rabaey ML
    Cancer Res; 1988 Apr; 48(7):1842-9. PubMed ID: 3349462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
    Speicher LA; Barone L; Tew KD
    Cancer Res; 1992 Aug; 52(16):4433-40. PubMed ID: 1353706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrotubule effects of estramustine, an antiprostatic tumor drug.
    Stearns ME; Tew KD
    Cancer Res; 1985 Aug; 45(8):3891-7. PubMed ID: 4016756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estramustine depolymerizes microtubules by binding to tubulin.
    Dahllöf B; Billström A; Cabral F; Hartley-Asp B
    Cancer Res; 1993 Oct; 53(19):4573-81. PubMed ID: 8402630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.
    Stearns ME; Wang M; Tew KD; Binder LI
    J Cell Biol; 1988 Dec; 107(6 Pt 2):2647-56. PubMed ID: 3060470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axonal transport in the frog sciatic nerve.
    Kanje M; Deinum J; Wallin M; Ekström P; Edström A; Hartley-Asp B
    Cancer Res; 1985 May; 45(5):2234-9. PubMed ID: 2580617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism based chemotherapy for prostate cancer.
    Sheridan VR; Tew KD
    Cancer Surv; 1991; 11():239-54. PubMed ID: 1841754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estramustine induces disorganization of microtubules, perinuclear retraction of vimentin and endoplasmatic reticulum, and inhibits cell migration.
    Rutberg M; Wallin M
    Acta Histochem; 1993 Dec; 95(2):155-67. PubMed ID: 8135088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of estramustine and its constituents on human malignant glioma cells.
    von Schoultz E; Lundgren E; Henriksson R
    Anticancer Res; 1990; 10(3):693-6. PubMed ID: 2369085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular effects of estramustine (Estracyt/Emcyt).
    Tew KD; Stearns ME
    Prog Clin Biol Res; 1989; 303():169-75. PubMed ID: 2674983
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of advanced oestrogen-resistant prostatic carcinoma with estramustine phosphate.
    Wong AL; McGeorge A; Abel BJ
    Clin Oncol; 1981 Jun; 7(2):163-5. PubMed ID: 7249439
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine.
    Tew KD; Stearns ME
    Urol Res; 1987; 15(3):155-60. PubMed ID: 3307087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine.
    Tew KD; Woodworth A; Stearns ME
    Cancer Treat Rep; 1986 Jun; 70(6):715-20. PubMed ID: 3731136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of advanced estrogen-resistant cancer of the prostate with estramustine phosphate. A phase-2 study].
    Trykker HU
    Ugeskr Laeger; 1985 Oct; 147(42):3310-2. PubMed ID: 4082315
    [No Abstract]   [Full Text] [Related]  

  • 18. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
    Ranganathan S; McCauley RA; Dexter DW; Hudes GR
    Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hormone-resistant prostate cancer with estramustine phosphate (Estracyt)].
    Stridsklev IC; Fosså SD; Kaalhus O
    Tidsskr Nor Laegeforen; 1984 Oct; 104(28):1977-80. PubMed ID: 6388019
    [No Abstract]   [Full Text] [Related]  

  • 20. Growth of prostatic cancer cells, DU 145, as multicellular spheroids and effects of estramustine.
    Essand M; Nilsson S; Carlsson J
    Anticancer Res; 1993; 13(5A):1261-8. PubMed ID: 8239495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.